deaths (OS)

endometrial cancer endometrial cancer

versus placebo plus SoC
durvalumab plus olaparib plus SoC vs. placebo plus SoC 1 certainty unassessable-38%

endometrial cancer - (neo)adjuvant (NA) endometrial cancer - (neo)adjuvant (NA)